Phase II trial of edatrexate in patients with metastatic colorectal cancer

Gerald H. Clamon; Charles E. Riggs; Robert Dreicer; Raymond J. Hohl

doi:10.1007/BF00873145

Phase II trial of edatrexate in patients with metastatic colorectal cancer

Gerald H. Clamon, Charles E. Riggs, Robert Dreicer, Raymond J. Hohl

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m²/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.

Original language	English (US)
Pages (from-to)	359-361
Number of pages	3
Journal	Investigational New Drugs
Volume	13
Issue number	4
DOIs	https://doi.org/10.1007/BF00873145
State	Published - Dec 1995

All Science Journal Classification (ASJC) codes

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00873145

Cite this

@article{4f49ef19f2bf47b0b990828e6f4a7ad3,

title = "Phase II trial of edatrexate in patients with metastatic colorectal cancer",

abstract = "Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.",

author = "Clamon, {Gerald H.} and Riggs, {Charles E.} and Robert Dreicer and Hohl, {Raymond J.}",

year = "1995",

month = dec,

doi = "10.1007/BF00873145",

language = "English (US)",

volume = "13",

pages = "359--361",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - Phase II trial of edatrexate in patients with metastatic colorectal cancer

AU - Clamon, Gerald H.

AU - Riggs, Charles E.

AU - Dreicer, Robert

AU - Hohl, Raymond J.

PY - 1995/12

Y1 - 1995/12

N2 - Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.

AB - Edatrexate is an analog of methotrexate which in vitro demonstrated activity against human colon cancer xenografts grown in nude mice. In a phase II trial, 12 patients with metastatic colorectal cancer and no prior chemotherapy were treated with Edatrexate 80 mg/m2/week for an initial period of 8 weeks. No objective responses were observed. Edatrexate is inactive against colon cancer at the dose and schedule used in this trial.

UR - http://www.scopus.com/inward/record.url?scp=0029582628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029582628&partnerID=8YFLogxK

U2 - 10.1007/BF00873145

DO - 10.1007/BF00873145

M3 - Article

C2 - 8824357

AN - SCOPUS:0029582628

SN - 0167-6997

VL - 13

SP - 359

EP - 361

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

Phase II trial of edatrexate in patients with metastatic colorectal cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this